Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug;105(2):116-125.
doi: 10.1111/ejh.13409. Epub 2020 May 26.

First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients

Wolfgang Knauf  1 , Gerrit Dingeldein  2 , Rudolf Schlag  3 , Manfred Welslau  4 , Thomas Moehler  5 , Tobias Terzer  6 , Sarah Walter  7 , Christina Habermehl  6 , Christina Kunz  6 , Hartmut Goldschmidt  8   9 , Marc-Steffen Raab  8 ; BPV trial group
Affiliations
Clinical Trial

First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients

Wolfgang Knauf et al. Eur J Haematol. 2020 Aug.

Abstract

Objectives: The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the three-drug combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM).

Methods: Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of nine cycles.

Results: Forty-six patients were included in the trial with a median age of 76 years. Nineteen patients had renal impairment at baseline. The ORR was 78.8% for patients treated with 3 and more BPV cycles and 71.1% for all evaluable patients. The median progression-free survival was 25 months, and overall survival at 24 months was 83.3%. The clinical benefit rate including MR was 91.2%. In patients with renal impairment at baseline, a renal response was observed in 11 pts. with complete recovery of the renal function in six patients. The most frequent CTC grade 3/4 AEs experienced by patients were hematological (17.5%) and infectious (9.8%) complications. No new safety signals were observed for the study drugs under investigation.

Conclusions: Bendamustine/prednisone/bortezomib may serve as a first-line regimen for transplant-ineligible elderly MM patients in particular for patients with renal impairment requiring a fast and durable renal response.

Keywords: clinical trials; multiple myeloma; non-Hodgkin's lymphoma; plasma cell neoplasms.

PubMed Disclaimer

References

REFERENCES

    1. Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematol. 2018;103:506-513.
    1. Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematol Am Soc Hematol Educ Program. 2017;2017:498-507.
    1. Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol. 2019;98:1-18.
    1. Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431-e442.
    1. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol. 2007;20:701-715.

Publication types

MeSH terms